Acute heart failure, chronic heart failure IIb-i stage (i-IV stage according to NYHA classification), supraventricular tachycardia, atrial fibrillation.
Release form, composition
The drug Strofantin is an injection solution that is produced in the form of a clear, colorless liquid.
The drug contains the active ingredient: strophanthin 0.25 mg.
Additional components: sodium hydroxide, citric acid monohydrate, water for injection.
The drug Strofantin belongs to the group of cardiotonic drugs.
The action of the drug promotes an increase in the speed and strength of myocardial contractility, a decrease in AV conduction, an increase in stroke and cardiac output, a decrease in heart rate, an improvement in ventricular release, which ultimately leads to an improvement in blood circulation.
Indications for use
The drug Strofantin is used and prescribed as part of complex treatment for chronic heart failure stage II (with classical manifestations) and stage III-IV according to the NYHA classification, acute heart failure, atrial fibrillation, supraventricular tachycardia.
It is contraindicated to inject a solution of Strofantin in the presence of such diseases:
- glycosidic intoxication;
- hypersensitivity to components;
- constrictive pericarditis;
- ventricular tachycardia;
- acute myocardial infarction;
- severe bradycardia;
- sick sinus syndrome;
- AV block II and III degrees;
- hypercalcemia and hypokalemia;
- hypertrophic obstructive cardiomyopathy;
- isolated mitral stenosis;
- acute myocarditis;
- carotid sinus syndrome;
- severe cardiosclerosis;
- Wolff-Parkinson-White syndrome;
- aneurysm of the thoracic aorta;
- children under 18 years of age.
Pregnancy and breastfeeding period
The introduction of the drug Strofantin during pregnancy and lactation is contraindicated.
Mode of application
The drug Strofantin is intended for intravenous use.
The recommended dose for adult patients is 1-2 ml of the drug, which is previously diluted in 10-20 ml of 0.9% sodium chloride solution.
If possible, it is advisable to inject the drug intravenously at a dosage of 1 ml diluted in 100 ml of 0.9% sodium chloride solution or 5% glucose solution.
If there is a need, a single dose can be increased, but not more than 2 ml (0.5 mg), the maximum daily dose should not exceed 4 ml (1 mg).
In case of an overdose of the drug Strofantin, the following are possible: cardiac arrhythmias and blockade, including bradycardia, ventricular extrasystole, ventricular paroxysmal tachycardia, polytopic gastric tachycardia, in especially severe cases, cardiac arrest and the development of ventricular fibrillation are possible;
Also, drug poisoning can cause: anorexia, vomiting, nausea, diarrhea, headache, intestinal wall necrosis, dizziness, neuritis, paresthesia, sciatica, decreased visual acuity, yellow and green color of the surrounding objects, scotomas, micro- and macropsia.
Very rarely, the administration of the solution leads to confusion, syncope and manic-depressive syndrome.
The use of the drug Strofantin can lead to the occurrence of such side effects: headache, confusion, dizziness, increased fatigue, sleep disturbances, drowsiness, mental disorders, visual impairment, nausea, loss of appetite, vomiting and diarrhea.
Also possible manifestations: thrombocytopenic purpura, petechiae, nosebleeds, conduction and heart rhythm disturbances, anaphylactic reactions, allergic reactions, urticaria, changes at the injection site.
In rare cases, a brigian heart attack and gynecomastia in men may occur.
Storage of the drug Strofantin does not require any special conditions: temperature not higher than +25 ° C, original packaging, dry and dark place, inaccessible to children.
The shelf life of the tablets is 5 years.